Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 8/20 | 0.52 |
| ▸ | RARG | P13631 | 8/20 | 0.52 |
| ▸ | RARA | P10276 | 7/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | CYP26A1 | O43174 | 3/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | VDR | P11473 | 4/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | RXRB | P28702 | 1/20 | 0.41 |
| ▸ | RXRG | P48443 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4709130 | 1.00 | RARB (0.52) | RARBRARGRARACYP3A4CYP26A1 | |
| SCHEMBL4666486 | 0.94 | RARB (0.50) | RARBRARGRARACYP3A4CYP26A1 | |
| SCHEMBL4666454 | 0.94 | RARB (0.50) | RARBRARGRARACYP3A4CYP26A1 | |
| SCHEMBL6909571 | 0.91 | RARB (0.52) | RARBRARGRARACYP3A4CYP26A1 | |
| SCHEMBL10842924 | 0.90 | RARB (0.55) | RARBRARGRARACYP3A4CYP26A1 | |
| SCHEMBL10842927 | 0.90 | RARB (0.55) | RARBRARGRARACYP3A4CYP26A1 | |
| SCHEMBL10843882 | 0.89 | RARA (0.50) | RARBRARGRARACYP3A4CYP26A1 | |
| SCHEMBL10843886 | 0.89 | RARA (0.50) | RARBRARGRARACYP3A4CYP26A1 | |
| SCHEMBL10847379 | 0.88 | RARB (0.49) | RARBRARGRARACYP3A4CYP26A1 | |
| SCHEMBL10847377 | 0.88 | RARB (0.49) | RARBRARGRARACYP3A4CYP26A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1324970-B1 | RETINOIDS FOR THE TREATMENT OF EMPHYSEMA | HOFFMANN LA ROCHE (CH) | 2008-11-05 | — | — | EP | disclosed |
| US-6777418-B2 | FOR TREATING OR PREVENTING EMPHYSEMA, CANCER AND DERMATOLOGICAL DISORDERS | SYNTEX (U.S.A.) LLC | 2004-08-17 | — | — | US | disclosed |
| US-20020082265-A1 | For treating or preventing emphysema, cancer and dermatological disorders | SYNTEX (U.S.A.) LLC | 2002-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082265-A1 | For treating or preventing emphysema, cancer and dermatological disorders | RXRA, RXRG, RXRB | RARB 6/4885RARG 4/4885RARA 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.